NDR Medical Technology Pte Ltd (NDR Medical) has secured funding through a financing round led by SGInnovate.
Based in Singapore, NDR Medical is a medical technology company engaged in developing a proprietary smart robotic guiding system called automated needle targeting (ANT).
The company plans to use the funds towards the development of a smart robotic guiding system for surgeons.
Olympus Corporation has entered a definitive agreement to purchase the lithotripsy systems of Cybersonics.
Olympus’ dual-action lithotripsy systems, including ShockPulse-SE and CyberWand, which are currently being manufactured by Cybersonics, will become part of the company’s urology portfolio, following the acquisition.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBased in Japan, Olympus is a precision machinery and instruments manufacturer, while Cybersonics is a US-based company specialising in the design and manufacturing of ultrasonic technology-based medical devices.
Acquisition of the lithography system will enable Olympus to improve clinical outcomes and enhance the quality of life for patients, while strengthening its position in the urology market in the US.
Inspire Medical Systems Inc (Inspire) plans to raise $86m through an initial public offering (IPO) of shares of its common stock.
The company has filed a registration statement with the US Securities and Exchange Commission for the IPO.
Inspire will grant the underwriters a 30-day option to purchase additional shares of common stock to cover over-allotments.
The company plans to use the funds for expanding its sales and marketing team, product development, working capital, and general corporate purposes.
Based in the US, Inspire is focused on the development of novel solutions for patients with obstructive sleep apnea (OSA).
US-based company Danaher Corporation plans to raise funds through a public offering of securities of its common stock.
Danaher plans to issue any combination of debt securities, common stock, preferred stock, warrants, depositary shares, purchase, and contracts in one or more offerings.
The funds are planned to be used for general corporate purposes, including the acquisition of businesses, repayment and refinancing of debts, and working capital.
Symmetry Surgical Inc has acquired LeMaitre Vascular’s general surgery product lines for use in laparoscopic cholecystectomy procedures for $7.4m.
The two companies have also entered a two-year manufacturing transition services agreement (TSA), as part of the transaction.
Based in the US, Symmetry Surgical is engaged in the manufacturing and marketing of medical devices, while LeMaitre, also based in the US, is a provider of peripheral vascular devices and implants.
Sotera Medical Corp has raised $1m through a seed financing round led by a syndicate of investors, including private investors, and the State of Ohio.
Based in the US, Sotera is focused on the development of devices for use in cardiac procedures.
The company plans to use the proceeds for further technological development, including first-in-human testing by the end of this year.
Akers Biosciences Inc has raised $0.81m through the private placement of 4.34 million shares of its common stock priced at $0.1875 a share.
Based in the US, Akers Biosciences is focused on the development, manufacture and distribution of rapid, point-of-care screening and testing products.
Camras Vision Inc has raised $5.7m through a series A financing round led by new and existing investors.
Based in the US, Camras is an ophthalmic medical devices developer and manufacturer.
The company plans to use the funds to support four clinical trials, including a US pilot study to evaluate the efficacy of its product for the treatment of refractory glaucoma.
